Format

Send to

Choose Destination
J Thorac Oncol. 2017 Aug;12(8):1183-1209. doi: 10.1016/j.jtho.2017.05.019. Epub 2017 Jun 1.

Scientific Advances in Thoracic Oncology 2016.

Author information

1
Cancer Science Institute of Singapore, National University of Singapore, Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, Singapore; School of Surgery, University of Western Australia, Perth, Australia.
2
Department of Thoracic Medicine, St. Vincent's Hospital, Kinghorn Cancer Centre, Sydney, Australia.
3
Hollings Cancer Center Medical University of South Carolina, Charleston, South Carolina.
4
National Jewish Health, Denver, Colorado.
5
Roy Castle Lung Cancer Research Programme, Department of Molecular and Clinical Cancer Medicine, The University of Liverpool, Liverpool, United Kingdom.
6
Department of Pulmonary Diseases, University Medical Center Groningen, Groningen, The Netherlands.
7
Internal Medicine, Graduate College, Rush University Medical Center, Chicago, Illinois.
8
Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.
9
Institute of Pathology, University Hospital Basel, Basel, Switzerland.
10
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
11
Department of Thoracic Surgery, Hospital Universitari Mutua Terrassa, University of Barcelona, Network of Biomedical Research Centers in Respiratory Diseases (CIBERES) Lung Cancer Group, Terrassa, Barcelona, Spain.
12
Department of Surgery, Yale University, New Haven, Connecticut.
13
Academic Division of Thoracic Surgery, The Royal Brompton Hospital and Imperial College, London, United Kingdom.
14
Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan.
15
Cardiothoracic Surgery, New York University School of Medicine, New York, New York.
16
Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, California.
17
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
18
Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia.
19
Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands.
20
Department of Medical Oncology, Peter MacCallum Cancer Center, Melbourne, Australia.
21
Seoul National University Hospital, Seoul, Republic of Korea.
22
Sarah Cannon Research Institute, Nashville, Tennessee.
23
Department of Oncology, National Taiwan University Hospital, Taipei, Republic of China.
24
Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
25
Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
26
Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
27
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois.
28
Division of Hematology/Oncology, Vanderbilt Ingram Cancer Center, Nashville, Tennessee.
29
Medical Oncology, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.
30
Medical Oncology and Thoracic Malignancies, Oncology Department, University Hospital Center Vaudois, Lausanne, Switzerland.
31
International Association for the Study of Lung Cancer, Aurora, Colorado.
32
Radiotherapy Related Research, Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital NHS Trust, Manchester, United Kingdom.
33
Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.
34
Mesothelioma Program, Thoracic Chemo-Radiation Program, Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas.
35
Department of Chest Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
36
Deptartment of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, Maryland.
37
Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
38
San Luigi Hospital, University of Turin, Orbassano, Italy.
39
Thoracic Oncology Program, University of California Davis Comprehensive Cancer Center, Sacramento, California.
40
Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora. Electronic address: Fred.Hirsch@ucdenver.edu.

Abstract

Lung cancer care is rapidly changing with advances in genomic testing, the development of next-generation targeted kinase inhibitors, and the continued broad study of immunotherapy in new settings and potential combinations. The International Association for the Study of Lung Cancer and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in thoracic cancer and care provide focused updates across multiple areas, including prevention and early detection, molecular diagnostics, pathology and staging, surgery, adjuvant therapy, radiotherapy, molecular targeted therapy, and immunotherapy for NSCLC, SCLC, and mesothelioma. Quality and value of care and perspectives on the future of lung cancer research and treatment have also been included in this concise review.

KEYWORDS:

Adjuvant therapy; Biomarkers; Cancer prevention; Immunotherapy; Malignant mesothelioma; Molecular diagnostics; NSCLC; Pathology; Radiotherapy; SCLC; Screening; Smoking cessation; Staging; Surgery; Targeted therapy; Value of therapy

PMID:
28579481
DOI:
10.1016/j.jtho.2017.05.019
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center